<DOC>
	<DOCNO>NCT01777191</DOCNO>
	<brief_summary>The purpose study evaluate serum concentration ixekizumab administration use either prefilled syringe auto-injector participant moderate severe plaque psoriasis . Treatment period follow 40 week optional safety extension .</brief_summary>
	<brief_title>Evaluation Ixekizumab Using Auto-Injector Prefilled Syringe Participants With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Present chronic plaque psoriasis base confirm diagnosis chronic psoriasis vulgaris least 6 month prior randomization At least 10 % Body Surface Area ( BSA ) Psoriasis screen randomization Static Physician Global Assessment ( sPGA ) score least 3 AND Psoriasis Area Severity Index ( PASI ) score least 12 screen randomization Candidate phototherapy and/or systemic therapy Men must agree use reliable method birth control study Women must agree use birth control remain abstinent study least 12 week stop treatment Pustular , erythrodermic , and/or guttate form psoriasis History druginduced psoriasis Clinically significant flare psoriasis 12 week prior randomization Concurrent recent use biologic agent Received systemic psoriasis therapy [ psoralen ultraviolet A ( PUVA ) light therapy ] phototherapy within previous 4 week ; topical psoriasis treatment within previous 2 week prior randomization Can avoid excessive sun exposure use tan booth least 4 week prior randomization study Have participate study interleukin17 ( IL17 ) antagonist , include Ixekizumab Serious disorder illness plaque psoriasis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>